Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

AB15322 Anti-Nicotinic Acetylcholine Receptor α4 Antibody

Detect Nicotinic Acetylcholine Receptor α4 using this Anti-Nicotinic Acetylcholine Receptor α4 Antibody validated for use in WB.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
Research Category: Neuroscience Research Sub-Category: Neurotransmitters & Receptors Gene Symbol: Acra4, Chrna4 UniProt Number: P09483
AB15322
100 µg  
Purchase on Sigma-Aldrich

Offres spéciales

Aperçu

Replacement Information

Offres spéciales

100% Performance Guaranteed

Tableau de caractéristiques principal

Species ReactivityKey ApplicationsHostFormatAntibody Type
M, R, HWBRbAffinity PurifiedPolyclonal Antibody
Description
Catalogue NumberAB15322
DescriptionAnti-Nicotinic Acetylcholine Receptor α4 Antibody
Alternate Names
  • Cholinergic receptor, nicotinic, alpha 4 (neuronal)
  • Cholinergic receptor, nicotinic, alpha polypeptide 4
  • Neuronal nicotinic acetylcholine receptor alpha-4 subunit
  • Neuronal acetylcholine receptor subunit alpha-4
Background InformationNicotinic acetylcholine receptors, or nAChRs, are cholinergic receptors that form ligand-gated ion channels in the plasma membranes of certain neurons. nAChR is triggered by the binding of the neurotransmitter acetylcholine (ACh) and is also opened by nicotine. After binding ACh, the nAChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. nAChRs are present in many tissues in the body: the neuronal receptors are present in the central nervous system and the peripheral nervous system; and the neuromuscular receptors are found in the neuromuscular junctions of somatic muscles. Neuronal AChR is composed of two different types of subunits: alpha (α) and beta (β).
References
Product Information
FormatAffinity Purified
Control
  • Rat e16 brain lysate
PresentationRabbit purified polyclonal serum in buffer containing 0.1 M Tris-Glycine (pH7.4) 150 mM NaCl with 0.05% sodium azide.
Quality LevelMQ100
Applications
ApplicationDetect Nicotinic Acetylcholine Receptor α4 using this Anti-Nicotinic Acetylcholine Receptor α4 Antibody validated for use in WB.
Key Applications
  • Western Blotting
Biological Information
ImmunogenThis antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from residues of Nicotinic Acetylcholine Receptor α4.
EpitopeExtracellular Domain
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityThis antibody recognizes Nicotinic Acetylcholine Receptor α4.
Species Reactivity
  • Mouse
  • Rat
  • Human
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryNicotinic acetylcholine receptor subunit responsible for binding calcium sensor protein visinin-like protein-1 (Vilip1), which modulates acetylcholine receptor expression and sensitivity [RGD].
Gene Symbol
  • Acra4
  • Chrna4
Modifications
  • Acetylation
Purification MethodAntigen Affinity Purified
UniProt Number
UniProt Summary"FUNCTION: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
SUBUNIT STRUCTURE: Pentamer of two alpha chains, and one each of the beta, delta, and gamma (in immature muscle) or epsilon (in mature muscle) chains.
SUBCELLULAR LOCATION: Cell junction › synapse › postsynaptic cell membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein.
TISSUE SPECIFICITY: Isoform 1 is only expressed in skeletal muscle whereas isoform 2 is constitutively expressed in skeletal muscle, brain, heart, kidney, liver, lung and thymus.
INVOLVEMENT IN DISEASE: Defects in CHRNA1 are a cause of lethal type multiple pterygium syndrome [MIM:253290]. Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.
The alpha subunit is the main focus for antibody binding in myasthenia gravis [MIM:254200]. Myasthenia gravis is characterized by sporadic muscular fatigability and weakness, occurring chiefly in muscles innervated by cranial nerves, and characteristically improved by cholinesterase-inhibiting drugs.
Defects in CHRNA1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
Defects in CHRNA1 are a cause of congenital myasthenic syndrome fast-channel type (FCCMS) [MIM:608930]. FCCMS is a congenital myasthenic syndrome characterized by kinetic abnormalities of the AChR. In most cases, FCCMS is due to mutations that decrease activity of the AChR by slowing the rate of opening of the receptor channel, speeding the rate of closure of the channel, or decreasing the number of openings of the channel during ACh occupancy. The result is failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.
SEQUENCE SIMILARITIES: Belongs to the ligand-gated ionic channel (TC 1.A.9) family. [View classification]
Molecular WeightApprox. 55 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by Western Blot in rat e16 brain lysate.
Western Blot Analysis: : 1:1,000 dilution of this lot detected Nicotinic Acetylcholine Receptor α4 in 10 µg of e16 rat brain lysate.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain refrigerated at 2-8°C for up to 12 months from date of receipt.
Packaging Information
Material Size100 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
AB15322 04053252366703

Documentation

Anti-Nicotinic Acetylcholine Receptor α4 Antibody FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

Anti-Nicotinic Acetylcholine Receptor α4 Antibody Certificats d'analyse

TitreNuméro de lot
Anti-Nicotinic Acetylcholine -2585767 2585767
Anti-Nicotinic Acetylcholine Receptor a4 - 2011475 2011475
Anti-Nicotinic Acetylcholine Receptor a4 - 2279272 2279272
Anti-Nicotinic Acetylcholine Receptor a4 - NG1628010 NG1628010
Anti-Nicotinic Acetylcholine Receptor a4 - NG1869251 NG1869251
Anti-Nicotinic Acetylcholine Receptor a4 - NG1922397 NG1922397
Anti-Nicotinic Acetylcholine Receptor alpha4 - NG1822437 NG1822437
Anti-Nicotinic Acetylcholine Receptor α4 2484226
Anti-Nicotinic Acetylcholine Receptor α4 - 2914942 2914942
Anti-Nicotinic Acetylcholine Receptor α4 - 3834500 3834500
Show more